Ascentage Pharma Group International (NASDAQ:AAPG) Hits New 12-Month Low – Here’s Why

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) hit a new 52-week low during trading on Friday . The company traded as low as $17.10 and last traded at $17.57, with a volume of 5393 shares. The stock had previously closed at $18.28.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. Deutsche Bank Aktiengesellschaft assumed coverage on Ascentage Pharma Group International in a report on Friday, April 24th. They set a “buy” rating and a $40.00 price target for the company. BTIG Research reiterated a “buy” rating and set a $48.00 price target on shares of Ascentage Pharma Group International in a report on Monday, April 13th. Finally, China Intl Cap upgraded Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, April 6th. Two equities research analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $46.67.

Ascentage Pharma Group International Price Performance

The company has a fifty day moving average price of $22.83 and a 200-day moving average price of $25.31. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.77 and a current ratio of 1.79.

Ascentage Pharma Group International (NASDAQ:AAPG) last issued its quarterly earnings data on Wednesday, March 25th. The company reported ($0.52) earnings per share for the quarter. The company had revenue of $24.72 million during the quarter. Equities analysts expect that Ascentage Pharma Group International – Unsponsored ADR will post -1.09 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. Citadel Advisors LLC bought a new position in shares of Ascentage Pharma Group International in the 3rd quarter valued at approximately $383,000. XY Capital Ltd raised its stake in shares of Ascentage Pharma Group International by 224.2% in the 3rd quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock valued at $707,000 after acquiring an additional 12,530 shares in the last quarter. UBS Group AG raised its stake in shares of Ascentage Pharma Group International by 149.4% in the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after acquiring an additional 10,988 shares in the last quarter. ABC Arbitrage SA bought a new position in shares of Ascentage Pharma Group International in the 3rd quarter valued at approximately $204,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Ascentage Pharma Group International in the 3rd quarter valued at approximately $96,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.